Prevest Denpro Ltd is Rated Sell

Mar 10 2026 10:10 AM IST
share
Share Via
Prevest Denpro Ltd is rated Sell by MarketsMojo, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Prevest Denpro Ltd is Rated Sell

Rating Overview and Context

On 06 November 2025, MarketsMOJO revised Prevest Denpro Ltd’s rating from 'Hold' to 'Sell', reflecting a significant change in the company’s overall assessment. The Mojo Score, a composite indicator of various performance parameters, dropped by 20 points from 51 to 31, signalling a more cautious stance towards the stock. This rating encapsulates a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical outlook.

Here’s How the Stock Looks Today

As of 10 March 2026, Prevest Denpro Ltd remains a microcap player in the Healthcare Services sector, with a Mojo Grade firmly in the 'Sell' category. The current market data reveals a mixed but predominantly subdued performance across key metrics, which underpin the rationale behind the present rating.

Quality Assessment

The company’s quality grade is assessed as average. Over the past five years, operating profit has grown at an annualised rate of 12.49%, indicating moderate but not robust growth. The latest half-year results ending December 2025 show flat performance, with a Return on Capital Employed (ROCE) at a relatively low 22.79%. Additionally, the Debtors Turnover Ratio stands at 6.53 times, the lowest in recent periods, suggesting some inefficiencies in receivables management. These factors collectively point to a business that is stable but lacks strong momentum or operational excellence to inspire confidence in sustained growth.

Valuation Considerations

Valuation metrics currently classify Prevest Denpro Ltd as expensive. The stock trades at a Price to Book Value ratio of 4.3, which is high relative to its sector peers and historical averages. Despite this, the stock is trading at a discount compared to the average historical valuations of its peer group, indicating some relative value. The Return on Equity (ROE) is 17%, which is respectable but does not fully justify the premium valuation. The Price/Earnings to Growth (PEG) ratio stands at 1.5, suggesting that the market expects moderate earnings growth but may be cautious about the sustainability of such growth. Investors should note that the stock’s valuation does not currently offer a compelling margin of safety.

Financial Trend Analysis

The financial trend for Prevest Denpro Ltd is flat, reflecting a lack of significant improvement or deterioration in recent periods. The company’s profits have risen by 17% over the past year, which is a positive sign. However, this has not translated into strong stock returns, as the share price has declined by 3.72% over the same period. The stock’s performance over various time frames is underwhelming: a 1-day gain of 0.84% contrasts with longer-term declines of 4.13% over one week, 8.15% over one month, 10.76% over three months, and a steep 30.56% over six months. Year-to-date, the stock is down 14.95%, and over the past year, it has marginally declined by 0.48%. These figures highlight a stock that is struggling to gain positive momentum despite some underlying profit growth.

Technical Outlook

The technical grade for Prevest Denpro Ltd is bearish. The stock’s recent price action and trend indicators suggest downward pressure, which aligns with the broader market sentiment and the company’s fundamental challenges. This bearish technical stance reinforces the cautious rating and signals that investors should be wary of potential further declines or volatility in the near term.

Additional Market Insights

Despite its presence in the healthcare services sector, Prevest Denpro Ltd has minimal institutional interest, with domestic mutual funds holding 0% of the company. This absence of significant institutional ownership may reflect concerns about the company’s valuation, growth prospects, or business model. Institutional investors typically conduct thorough on-the-ground research, and their lack of participation can be a red flag for retail investors.

Furthermore, the stock has underperformed the BSE500 index over the last three years, one year, and three months, indicating that it has not kept pace with broader market gains. This underperformance, combined with flat financial trends and a bearish technical outlook, supports the current 'Sell' rating.

Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!

  • - Latest weekly selection
  • - Target price delivered
  • - Large Cap special pick

See This Week's Special Pick →

What the 'Sell' Rating Means for Investors

MarketsMOJO’s 'Sell' rating on Prevest Denpro Ltd suggests that investors should exercise caution and consider reducing exposure to this stock. The rating reflects a combination of average operational quality, expensive valuation, flat financial trends, and bearish technical signals. For investors, this means the stock currently carries higher risk relative to potential reward, and there may be better opportunities elsewhere in the healthcare services sector or broader market.

Investors should also be mindful that the rating and analysis are based on the most recent data as of 10 March 2026, ensuring that decisions are informed by the latest available information rather than historical snapshots. The 'Sell' rating does not imply an immediate sell-off but rather a recommendation to reassess the stock’s place within a diversified portfolio and to monitor developments closely.

Summary

In summary, Prevest Denpro Ltd’s current 'Sell' rating is justified by its modest growth prospects, high valuation metrics, flat financial performance, and negative technical outlook. The stock’s underperformance relative to market benchmarks and lack of institutional backing further reinforce the cautious stance. Investors should weigh these factors carefully and consider alternative investments with stronger fundamentals and more favourable valuations.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News